Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028

Aclaris Therapeutics, Inc.

2024-Q3 EPS reported -$0.50 revenue$9,509,000

Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.
R&D expenses dropped to $6.0M from $23.9M, driven by reduced clinical and manufacturing costs.
Cash, equivalents and marketable securities of $173.4M expected to fund operations into 2028.
First patient dosed in Phase 2a trial of ATI-2138 for atopic dermatitis; top-line data expected H1 2025.
Seeking global development partner for lepzacitinib (ATI-1777) after positive Phase 2b in atopic dermatitis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.